Km Biologics Co., Ltd.

Miyuki Matsumoto

Hiroyuki Shimizu

Masaharu Torikai

Hiroaki Mori

Tomohiro Nishimura

Naoki Inoue

Toshihiro Nakashima

Kenji Soejima

Akihiro Koube

Takahiro Katayama

Kohsuke Hazeyama

Takamasa Nagatomo

An object of the present invention is to provide an effective vaccine capable of preventing and treating congenital infection with CMV. The vaccine for preventing or treating congenital infection with cytomegalovirus (CMV) according to the present invention comprises a CMV envelope glycoprotein B (gB protein) antigen and a pentamer antigen.

Vaccine for preventing or treating congenital infection with cytomegalovirus

The present invention is directed to provide a modified CMV gB protein that can induce a group of antibodies including a high ratio of neutralizing antibodies that exhibit a high neutralizing activity against a CMV gB protein, in comparison with a wild type CMV gB, upon induction of immunity and that can be used in the prevention and/or treatment of CMV infection and a CMV vaccine comprising the modified CMV gB protein. The modified CMV gB protein according to the present invention is a modified CMV gB protein having an improved ability to induce body region-recognizing antibodies and comprising modification in a head region.

Modified CMV gB protein and CMV vaccine including same

A modified protein of a herpes simplex virus (HSV) envelope glycoprotein B (gB), in which at least one non-neutralizing antibody-inducing epitope (non-neutralizing epitope) present in domain IV and domain I of wild-type HSV gB is inactivated (de-epitoped).

Modified HSV gB protein and HSV vaccine including same

The present invention relates to a human anti-human IL-18 antibody which reacts with human interleukin-18 (human IL-18) and does not react with a K53A variant of human IL-18.

Human antibody against IL-18

Growing community of inventors

Kikuchi, Japan

Miyuki Matsumoto